{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:41Z","timestamp":1790251841948,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973999"],"award-info":[{"award-number":["81973999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370660"],"award-info":[{"award-number":["81370660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270184"],"award-info":[{"award-number":["82270184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03053-7","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:19:06Z","timestamp":1785482346000},"page":"2298-2308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting ACSF2 overcomes Ara-C resistance in acute myeloid leukemia via the cholesterol metabolism-ERK signaling axis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-8750","authenticated-orcid":false,"given":"Chenxi","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-2999","authenticated-orcid":false,"given":"Jin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-4188","authenticated-orcid":false,"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4293-296X","authenticated-orcid":false,"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4579-7896","authenticated-orcid":false,"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0321","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-459X","authenticated-orcid":false,"given":"Lingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3385-6140","authenticated-orcid":false,"given":"Danyue","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"3053_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"3053_CR2","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75:46\u201367.","journal-title":"CA Cancer J Clin"},{"key":"3053_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"3053_CR4","doi-asserted-by":"crossref","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29.","DOI":"10.1186\/s13045-023-01424-6"},{"key":"3053_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 2024;10:1417\u201325.","journal-title":"JAMA Oncol"},{"key":"3053_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"3053_CR7","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","volume":"7","author":"S Turkalj","year":"2023","unstructured":"Turkalj S, Radtke FA, Vyas P. An overview of targeted therapies in acute myeloid leukemia. Hemasphere. 2023;7:e914.","journal-title":"Hemasphere"},{"key":"3053_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"3053_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.27584","volume":"100","author":"CG Moore","year":"2025","unstructured":"Moore CG, Stein A, Fathi AT, Pullarkat V. Treatment of relapsed\/refractory AML: novel treatment options including immunotherapy. Am J Hematol. 2025;100:23\u201337.","journal-title":"Am J Hematol"},{"key":"3053_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649\u201364.e20.","journal-title":"Cell"},{"key":"3053_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1194\/jlr.M700378-JLR200","volume":"48","author":"PA Watkins","year":"2007","unstructured":"Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res. 2007;48:2736\u201350.","journal-title":"J Lipid Res"},{"key":"3053_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70358","volume":"6","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Yan W, Tong L, Yang J, Ge S, Fan J, et al. Metabolic reprogramming: a crucial contributor to anticancer drug resistance. MedComm. 2025;6:e70358.","journal-title":"MedComm"},{"key":"3053_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/s41375-025-02645-z","volume":"39","author":"V Dembitz","year":"2025","unstructured":"Dembitz V, James SC, Gallipoli P. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 2025;39:1814\u201323.","journal-title":"Leukemia"},{"key":"3053_CR14","doi-asserted-by":"crossref","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724.e4.","DOI":"10.1016\/j.ccell.2018.10.005"},{"key":"3053_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"N van Gastel","year":"2020","unstructured":"van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, et al. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metab. 2020;32:391\u2013403.e6.","journal-title":"Cell Metab"},{"key":"3053_CR16","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792\u20138.","journal-title":"Haematologica"},{"key":"3053_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353\u201366.","journal-title":"Haematologica"},{"key":"3053_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.cmet.2021.09.001","volume":"33","author":"Y Song","year":"2021","unstructured":"Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021;33:1911\u201325.","journal-title":"Cell Metab"},{"key":"3053_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cell.2012.02.035","volume":"148","author":"J Nunnari","year":"2012","unstructured":"Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145\u201359.","journal-title":"Cell"},{"key":"3053_CR20","doi-asserted-by":"publisher","first-page":"D39","DOI":"10.1093\/nar\/gkac907","volume":"51","author":"WK Shen","year":"2023","unstructured":"Shen WK, Chen SY, Gan ZQ, Zhang YZ, Yue T, Chen MM, et al. AnimalTFDB 4.0: a comprehensive animal transcription factor database updated with variation and expression annotations. Nucleic Acids Res. 2023;51:D39\u2013D45.","journal-title":"Nucleic Acids Res"},{"key":"3053_CR21","doi-asserted-by":"publisher","first-page":"D165","DOI":"10.1093\/nar\/gkab1113","volume":"50","author":"JA Castro-Mondragon","year":"2022","unstructured":"Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50:D165\u2013D73.","journal-title":"Nucleic Acids Res"},{"key":"3053_CR22","doi-asserted-by":"publisher","first-page":"D104","DOI":"10.1093\/nar\/gkaa1057","volume":"49","author":"S Kolmykov","year":"2021","unstructured":"Kolmykov S, Yevshin I, Kulyashov M, Sharipov R, Kondrakhin Y, Makeev VJ, et al. GTRD: an integrated view of transcription regulation. Nucleic Acids Res. 2021;49:D104\u2013D11.","journal-title":"Nucleic Acids Res"},{"key":"3053_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710\u201330.","journal-title":"Nat Rev Endocrinol"},{"key":"3053_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.04.022","volume":"11","author":"Y He","year":"2024","unstructured":"He Y, Qi S, Chen L, Zhu J, Liang L, Chen X, et al. The roles and mechanisms of SREBP1 in cancer development and drug response. Genes Dis. 2024;11:100987.","journal-title":"Genes Dis"},{"key":"3053_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cac2.70038","volume":"45","author":"M Lao","year":"2025","unstructured":"Lao M, Zhang X, Li Z, Sun K, Yang H, Wang S, et al. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Commun. 2025;45:1010\u201337.","journal-title":"Cancer Commun"},{"key":"3053_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41420-025-02354-7","volume":"11","author":"G Wei","year":"2025","unstructured":"Wei G, Huang Y, Li W, Xie Y, Zhang D, Niu Y, et al. SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance. Cell Death Discov. 2025;11:75.","journal-title":"Cell Death Discov"},{"key":"3053_CR27","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.18632\/aging.204323","volume":"14","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Liu M, Xu Z, Cai Y, Peng B, Liang Q, et al. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma. Aging. 2022;14:7926\u201340.","journal-title":"Aging"},{"key":"3053_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.708699","volume":"12","author":"Y Song","year":"2021","unstructured":"Song Y, Tian S, Zhang P, Zhang N, Shen Y, Deng J. Construction and validation of a novel ferroptosis-related prognostic model for acute myeloid leukemia. Front Genet. 2021;12:708699.","journal-title":"Front Genet"},{"key":"3053_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2022.106671","volume":"163","author":"M Wang","year":"2022","unstructured":"Wang M, Su Y, Hou C, Ren K, Liu X, Zhao S, et al. Targeted lipidomics analysis of lysine 179 acetylation of ACSF2 in rat hepatic stellate cells. Prostaglandins Other Lipid Mediat. 2022;163:106671.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"3053_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.freeradbiomed.2023.02.003","volume":"198","author":"H Shi","year":"2023","unstructured":"Shi H, Qi H, Xie D, Zhuang J, Qi H, Dai Y, et al. Inhibition of ACSF2 protects against renal ischemia\/reperfusion injury via mediating mitophagy in proximal tubular cells. Free Radic Biol Med. 2023;198:68\u201382.","journal-title":"Free Radic Biol Med"},{"key":"3053_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3053_CR32","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.leu.2403859","volume":"19","author":"MR Ricciardi","year":"2005","unstructured":"Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single-cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19:1543\u20139.","journal-title":"Leukemia"},{"key":"3053_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2403032","volume":"17","author":"P Lunghi","year":"2003","unstructured":"Lunghi P, Tabilio A, Dall\u2019Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003;17:1783\u201393.","journal-title":"Leukemia"},{"key":"3053_CR34","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/leu.2015.137","volume":"29","author":"K Morita","year":"2015","unstructured":"Morita K, Masamoto Y, Kataoka K, Koya J, Kagoya Y, Yashiroda H, et al. BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia. 2015;29:2248\u201356.","journal-title":"Leukemia"},{"key":"3053_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-020-01658-z","volume":"39","author":"Y Pang","year":"2020","unstructured":"Pang Y, Zhao Y, Wang Y, Wang X, Wang R, Liu N, et al. TNFAIP8 promotes AML chemoresistance by activating the ERK signaling pathway through interaction with Rac1. J Exp Clin Cancer Res. 2020;39:158.","journal-title":"J Exp Clin Cancer Res"},{"key":"3053_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s11658-024-00629-y","volume":"29","author":"Q Jin","year":"2024","unstructured":"Jin Q, Qi D, Zhang M, Qu H, Dong Y, Sun M, et al. CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. Cell Mol Biol Lett. 2024;29:112.","journal-title":"Cell Mol Biol Lett"},{"key":"3053_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07661-6","volume":"16","author":"F Yin","year":"2025","unstructured":"Yin F, Yang J, Luo H, Yu T, Lu W, Zhao M, et al. Targeting oncogenic activation of FLT3\/SREBP\/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids. Cell Death Dis. 2025;16:327.","journal-title":"Cell Death Dis"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03053-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:37Z","timestamp":1790250217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03053-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03053-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Ethics Committee of Union Hospital, Huazhong University of Science and Technology (Number # 0692), and informed consent was obtained from all participants. The animal experiment was approved by the Ethics Committee of Huazhong University of Science and Technology (Number # 5150) and carried out in compliance with accepted standards for animal welfare.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}